A drug called palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer.
Targeting cancer cells with a transcription elongation inhibitor delayed tumor progression in animal models, according to a recent Northwestern Medicine study.
In a recent clinical trial, a drug called apalutamide added to standard therapy slowed cancer progression in men with prostate cancer, while maintaining quality of life.
Northwestern Medicine investigators are leading a Specialized Program of Research Excellence (SPORE) in brain cancer with a special emphasis on glioblastoma.
A new study has identified genes that, when inhibited, may slow or stop the progression of primary effusion lymphoma.
Faculty, family and friends gathered at a symposium to honor Robert Goldman, PhD, chair of Cell and Molecular Biology, and his distinguished scientific career.
A novel chemotherapy regimen led to improved outcomes for older patients with Hodgkin lymphoma, similar to those of younger patients, according to a Northwestern Medicine clinical trial.
Led by Melissa Simon, MD, MPH, the Center for Health Equity Transformation will build research infrastructure, conduct workforce development and support community partners in the effort to advance population health equity.
A protein facilitating DNA replication during cell cycle also binds microtubules, findings that could inform more effective cancer treatments, according to a recent study published in the Journal of Cell Biology.